Join
Live feed
·
PRReleasevia Quantisnow
BioCryst Pharmaceuticals Inc. logo

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

ByQuantisnow·Wall Street's wire, on your screen.
BCRX· BioCryst Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BCRX (BioCryst Pharmaceuticals Inc.) and more on Quantisnow.